Insider Selling: Avalo Therapeutics (NASDAQ:AVTX) CFO Sells $179,459.70 in Stock

Avalo Therapeutics, Inc. (NASDAQ:AVTX) CFO Christopher Sullivan sold 10,185 shares of the stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $17.62, for a total transaction of $179,459.70. Following the sale, the chief financial officer directly owned 39,900 shares of the company’s stock, valued at approximately $703,038. This trade represents a 20.34% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Avalo Therapeutics Price Performance

Shares of AVTX stock opened at $16.12 on Monday. Avalo Therapeutics, Inc. has a fifty-two week low of $9.54 and a fifty-two week high of $24.27. The firm’s 50 day moving average price is $19.07 and its two-hundred day moving average price is $17.07. The stock has a market cap of $864.52 million, a price-to-earnings ratio of -3.69 and a beta of 0.78.

Avalo Therapeutics (NASDAQ:AVTX) last posted its earnings results on Thursday, August 6th. The company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.25). On average, equities analysts forecast that Avalo Therapeutics, Inc. will post -2.69 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on AVTX shares. Weiss Ratings raised shares of Avalo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Leerink Partners started coverage on Avalo Therapeutics in a research report on Monday, July 6th. They set an “outperform” rating and a $38.00 target price on the stock. Bank of America assumed coverage on Avalo Therapeutics in a report on Friday, June 12th. They issued a “buy” rating and a $35.00 price target for the company. BTIG Research restated a “buy” rating and set a $58.00 price objective on shares of Avalo Therapeutics in a report on Tuesday, June 16th. Finally, Guggenheim set a $48.00 target price on Avalo Therapeutics and gave the company a “buy” rating in a research report on Friday, August 7th. Twelve research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $45.10.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. California State Teachers Retirement System bought a new stake in shares of Avalo Therapeutics in the 2nd quarter valued at approximately $196,000. Dimensional Fund Advisors LP acquired a new position in Avalo Therapeutics in the third quarter worth $143,000. Boothbay Fund Management LLC bought a new stake in Avalo Therapeutics during the second quarter valued at $56,000. AlphaCentric Advisors LLC bought a new stake in Avalo Therapeutics during the first quarter valued at $174,000. Finally, Jump Financial LLC acquired a new stake in shares of Avalo Therapeutics during the fourth quarter worth $238,000. Institutional investors own 87.06% of the company’s stock.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies for immune-mediated and inflammatory diseases. The company’s research strategy centers on treatments intended to address conditions in which abnormal immune system activity contributes to disease progression.

Avalo’s lead product candidate is AVTX-009, an investigational fully human monoclonal antibody designed to inhibit interleukin-1 beta (IL-1β), a signaling protein involved in inflammation.